TAK Stock Price, Chart, Stats & News

Takeda Pharmaceutical Company Limited
Save
TAK chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 62.11% |
Operating margin | 8.31% |
Pretax margin | 4.63% |
Net margin | 2.56% |
Effective tax rate | 44.63% |
ROA | 0.74% |
ROE | 1.61% |
D/E | 0.64x |
Interest coverage ratio | 1.18x |
TAK valuation
P/E | 42.16x |
P/S | 2.02x |
P/B | 1.19x |
P/CF | 7.71x |
P/FCF | 9.48x |
P/OCF | 7.71x |
PEG | 0.00x |
EV multiple | 3.49x |
About
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands.
Similar securities
Based on sector and market capitalization
Report issue











